Navigation Links
Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
Date:2/7/2008

SEATTLE, Feb. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., chairman and chief executive officer of Dendreon, will present a company update at the 10th Annual BIO CEO & Investor Conference in New York City, on Wednesday, February 13, 2008 at 1:15 p.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
2. Dendreon Reports Third Quarter 2007 Financial Results
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Secures $130 Million Committed Equity Financing Facility
5. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
8. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
9. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
10. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  In Atlanta, it seems everyone has ... culture intertwine to create an expressive and dynamic community unlike ... energy and contribute to it. With their ... Fairies seeks to carry on that tradition with a ... Atlanta salon is the newest of 13 nationwide ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... published evaluation of multiple immunoassay-based threat detection technologies by researchers from the ... CANARY® biosensor threat detection technology was found to have the best level ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), ... medical conditions, today announced that Linda Marbán, Ph.D, president and ... investor conferences: Cowen and Company 37th ... am ET Boston, MA ... 9:00 am PT (12:00 pm ET) Dana Point, ...
(Date:2/22/2017)... Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a ... of innovative biopharmaceutical products for companion animals, will host a ... a.m. ET to discuss financial results from the fourth quarter ... Interested participants and investors may access the audio webcast ... ...
Breaking Biology Technology:
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
(Date:1/24/2017)...  It sounds simple and harmless—an electronic sensor ... signs and alerts parents on their smart phones ... drops. But pediatric experts argue that such devices ... evidence of medical benefits, especially to healthy babies. ... parents of healthy babies, promising peace of mind ...
Breaking Biology News(10 mins):